Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study - Summary - MDSpire

Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study

  • By

  • Frederique St-Pierre

  • Subodh Bhatta

  • Peter G. Doukas

  • Madeline Jenkin

  • Kaitlin Annunzio

  • Alexandra E. Rojek

  • Alyssa Gibson

  • Yun Kyoung Tiger

  • Brittany McCall

  • Khaled Alhamad

  • Alec Hansen

  • Juan P. Alderuccio

  • Olutobi Adewale

  • Keem Patel

  • Asaad Trabolsi

  • Izidore S. Lossos

  • Lindsey Fitzgerald

  • Thomas A. Ollila

  • Matthew J. Matasar

  • Justin Kline

  • Reem Karmali

  • Narendranath Epperla

  • June 21, 2025

  • 0 min

Share

Objective:

To evaluate outcomes and toxicities in patients with extranodal (EN) relapsed or refractory large B-cell lymphoma (LBCL) undergoing CAR T-cell therapy, specifically focusing on the impact of EN involvement.

Key Findings:
  • 218 patients included; median age 62 years, 64% male. 62% had 1 EN site involved; most common sites were skin/soft tissue (25%), bone (22%), and lung (17%). Overall response rate (ORR) was 62%, and complete response rate (CRR) was 40%, indicating significant therapeutic efficacy. Cytokine release syndrome (CRS) occurred in 73% of patients; immune effector cell-associated neurotoxicity syndrome (ICANS) in 37%. Prolonged need for transfusions and granulocyte colony-stimulating factor was observed in 19% and 36% of patients, respectively, highlighting the need for careful monitoring.
Interpretation:

Extranodal involvement in R/R LBCL patients undergoing CAR T-cell therapy is associated with significant response rates and manageable toxicities, although outcomes may vary considerably based on the specific site of EN involvement.

Limitations:
  • Retrospective design may introduce selection bias, potentially affecting the generalizability of the findings. Limited data on specific EN sites due to low prevalence may also impact the robustness of conclusions drawn.
Conclusion:

This study highlights the need for further research on the impact of EN involvement on CAR T-cell therapy outcomes in R/R LBCL, given the heterogeneity of the disease and its implications for treatment strategies.

Original Source(s)

Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study

  • by Frederique St-Pierre, Subodh Bhatta, Peter G. Doukas, Madeline Jenkin, Kaitlin Annunzio, Alexandra E. Rojek, Alyssa Gibson, Yun Kyoung Tiger, Brittany McCall, Khaled Alhamad, Alec Hansen, Juan P. Alderuccio, Olutobi Adewale, Keem Patel, Asaad Trabolsi, Izidore S. Lossos, Lindsey Fitzgerald, Thomas A. Ollila, Matthew J. Matasar, Justin Kline, Reem Karmali, Narendranath Epperla

  • June 21, 2025

Related Content